Bioxis
Bioxis Pharmaceuticals is a cutting-edge company specializing in the discovery, development, production, and commercialization of innovative regenerative medical products. Based in Lyon, France, Bioxis focuses on creating next-generation dermal fillers and other aesthetic solutions that help regenerate tissues and improve patient outcomes. Their leading product, MTI-12, is an ultra-pure chitosan tissular inductor designed to enhance tissue regeneration and aesthetic treatments. Bioxis is known for its advanced biomaterials technology, particularly in the development of hyaluronic acid-based dermal fillers under the brand CYTOSIAL. These products are distributed across Europe and Asia through exclusive agreements. The company is supported by major organizations such as Medicen Paris Region, CNRS, and BPI France, ensuring the highest standards of innovation and quality in the aesthetic dermatology field. Bioxis is committed to providing revolutionary solutions that transform the medical aesthetics landscape.
Bioxis Introduction
Based in France, Bioxis specializes in the discovery, development, production and commercialization of innovative regenerative medicine products. Through groundbreaking solutions, the company develops popular products that help doctors improve quality of care. Their lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and their hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.